RU2013108394A - Соединения и способы восстановления кожи - Google Patents

Соединения и способы восстановления кожи Download PDF

Info

Publication number
RU2013108394A
RU2013108394A RU2013108394/15A RU2013108394A RU2013108394A RU 2013108394 A RU2013108394 A RU 2013108394A RU 2013108394/15 A RU2013108394/15 A RU 2013108394/15A RU 2013108394 A RU2013108394 A RU 2013108394A RU 2013108394 A RU2013108394 A RU 2013108394A
Authority
RU
Russia
Prior art keywords
composition
alkyl
alkenyl
combinations
compound
Prior art date
Application number
RU2013108394/15A
Other languages
English (en)
Russian (ru)
Inventor
Гуан Л. ЦЗЯН
Роберт М. БЕРК
Вха Бин ИМ
Фредерик К. БЕДДИНГФИЛД
Ларри А. УИЛЕР
Скотт М. Виткап
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2013108394A publication Critical patent/RU2013108394A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
RU2013108394/15A 2010-07-30 2011-07-29 Соединения и способы восстановления кожи RU2013108394A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US61/369,232 2010-07-30
US41911510P 2010-12-02 2010-12-02
US61/419,115 2010-12-02
PCT/US2011/045833 WO2012016109A2 (en) 2010-07-30 2011-07-29 Compounds and methods for skin repair

Publications (1)

Publication Number Publication Date
RU2013108394A true RU2013108394A (ru) 2014-09-10

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013108394/15A RU2013108394A (ru) 2010-07-30 2011-07-29 Соединения и способы восстановления кожи

Country Status (18)

Country Link
US (1) US20120136011A1 (enExample)
EP (1) EP2598140B1 (enExample)
JP (1) JP2013536183A (enExample)
KR (1) KR20130130694A (enExample)
CN (1) CN103068382A (enExample)
AR (1) AR082428A1 (enExample)
AU (1) AU2011282549A1 (enExample)
BR (1) BR112013002319A2 (enExample)
CA (1) CA2806982A1 (enExample)
CL (1) CL2013000308A1 (enExample)
CO (1) CO6680670A2 (enExample)
MX (1) MX2013001227A (enExample)
NZ (1) NZ607306A (enExample)
PH (1) PH12013500205A1 (enExample)
RU (1) RU2013108394A (enExample)
SG (1) SG187653A1 (enExample)
TW (1) TW201210601A (enExample)
WO (1) WO2012016109A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
CA2891595A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2014078446A2 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
CA2924843A1 (en) * 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
TWI593403B (zh) 2016-12-01 2017-08-01 徐藝庭 遺體臉部毀損之修復方法
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
JP5319065B2 (ja) * 2003-02-11 2013-10-16 アラーガン インコーポレイテッド 眼圧降下剤としての１０，１０−ジアルキルプロスタン酸誘導体
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
EP1782829A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
JP2010513551A (ja) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物
CN101686985A (zh) * 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Also Published As

Publication number Publication date
CN103068382A (zh) 2013-04-24
TW201210601A (en) 2012-03-16
CO6680670A2 (es) 2013-05-31
BR112013002319A2 (pt) 2016-05-24
AU2011282549A1 (en) 2013-02-28
EP2598140B1 (en) 2015-01-14
NZ607306A (en) 2015-03-27
MX2013001227A (es) 2013-04-24
WO2012016109A3 (en) 2012-03-22
US20120136011A1 (en) 2012-05-31
PH12013500205A1 (en) 2017-08-23
JP2013536183A (ja) 2013-09-19
AR082428A1 (es) 2012-12-05
CL2013000308A1 (es) 2013-04-12
SG187653A1 (en) 2013-03-28
KR20130130694A (ko) 2013-12-02
EP2598140A2 (en) 2013-06-05
WO2012016109A2 (en) 2012-02-02
CA2806982A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
RU2013129262A (ru) Соединения и способы для восстановления кожи
JP2013536183A5 (enExample)
JP2013544842A5 (enExample)
EP2598140B1 (en) Prostanoid ep4 agonists for use in treating a skin blemish
KR20100098633A (ko) 자색반병의 치료를 위한 조성물 및 방법
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
WO2012065065A9 (en) Methods and compositions for modulating hair growth, wound healing and scar revision
ECSP22011746A (es) Agentes antipalúdicos
BR112013033363A2 (pt) composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma
KR20190038840A (ko) 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
CN1555252A (zh) 用于鸟氨酸脱羧酶抑制剂毛囊传输的外用组合物
RU2015148910A (ru) Альфа-адренергические агонисты для лечения повреждения тканей
EA201270784A1 (ru) Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания
JP2015537028A5 (enExample)
MX2023003569A (es) Tratamiento de padecimientos dermatologicos.
US20170143733A1 (en) Compounds and methods for skin repair
RU2016110925A (ru) Простагландин f2 альфа и его аналоги для лечения атрофического кожного рубцевания
MX2021000207A (es) Regímenes de dosificación para el tratamiento de daños en los tejidos asociados a la hipoxia.
JP2016531872A5 (enExample)
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
JP2018534358A (ja) Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
US20100144746A1 (en) Method for restructuring a biological tissue comprising collagen fibrils and relative uses
TWI624288B (zh) 一種分層治療皮膚的系統
CN105992586A (zh) 促进伤口愈合的药物组合物

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160309